Eisai Co., Ltd.
4523.T
Below: live stock price for Eisai Co., Ltd. (4523.T), a 1-year chart, 8 indicators (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volume), and a compare mode. Add to your portfolio, star to your watchlist, or set a price alert in one place.
Eisai Co., Ltd. (4523.T) is a Healthcare company based in Japan. Operating in Drug Manufacturers - Specialty & Generic, it employs about 10,543 people. Over the past year 4523.T traded between 3,660 and 5,243 JPY. Trailing P/E sits near 36.94 on a market cap of about 1.43T JPY. It currently yields 3.17% in dividends.
- Prev close
- $31.58
- Volume (24h)
- $43.11M
- Market cap
- $9.05B
- Currency
- USD (native JPY)
Score
45/ 100 · Mixed
- Value32
- Quality49
- Momentum41
- Growth54
- Risk57
- Dividend22
- Liquidity60
Composite of public market data. Informational only — not investment advice.
Trend projection
Where the recent trend points if it continues.
- +5 bars
- 32.1637 +0.27%
- +20 bars
- 32.2832 +0.64%
- +60 bars
- 32.3296 +0.79%
- +120 bars
- 32.3313 +0.79%
Linear-regression continuation — not a prediction, not investment advice. ±1σ ≈ 68% range · ±2σ ≈ 95% range: 1σ ≈ ±1.54% per bar.
Interpretation
Composite signals look mixed. Strength: balance-sheet liquidity with weakness: dividend. Price sits near the upper third of the recent range, trend is roughly flat.
Descriptive observation — not investment advice.
Score breakdown
Raw values behind each pillar so you can see what the composite is reading.
- Value32/100
Value looks weak — driven by P/E (36.94).
P/E:36.94P/B:1.57PEG:26.43 - Quality49/100
Quality looks mixed — driven by Gross margin (76.70%).
ROE:4.96%ROA:2.40%Profit margin:4.94%Gross margin:76.70% - Momentum41/100
Momentum looks weak — driven by 52w change (11.45%).
52w change:11.45% - Growth54/100
Growth looks mixed — driven by Earnings growth (26.00%).
Revenue growth:15.60%Earnings growth:26.00% - Risk57/100
Risk looks mixed — driven by Debt / equity (29.08).
Beta:-0.09Debt / equity:29.08 - Dividend22/100
Dividend looks fragile — driven by Payout ratio (116.98%).
Dividend yield:3.17%Payout ratio:116.98% - Liquidity60/100
Liquidity looks solid — driven by Current ratio (2.24).
Current ratio:2.24Quick ratio:1.44
Derived from public market data — informational, not investment advice.
Price report
How this asset has actually moved over the last 242 days.
Where the price sits between the window low and high.
- Volatility (annualised)
- 30.1%
- Max drawdown
- -29.0%
- Below period high
- -3.6%
- Best day
- +7.40%
- Worst day
- -6.22%
- Up days
- 53%
- Current streak
- 1 up
- Typical day swing
- 2.2%
- Volume vs average
- +2%
Spread of returns. Higher means larger swings in both directions.
Worst peak-to-trough fall inside the window.
Current price against the highest point in the window.
Share of days that closed above the one before.
Average high-to-low spread within a single day.
Last 10 days against the whole window.
Descriptive statistics over past prices — not a forecast and not investment advice.
Reference levels
Fibonacci retracements and extensions across the recent range.
Reference only — not investment advice.
These coordinates describe past-trade clustering, not where to buy or sell. Do your own research before any trade.
Levels derived from: 32.9663 high → 28.4201 low · 60 bars
- ResistanceFib +161.8% extensionnot reached40.322 USD+25.70% from current
- ResistanceFib +100% extensionnot reached37.5125 USD+16.94% from current
- ResistanceFib +61.8% extensionnot reached35.7758 USD+11.53% from current
- ResistanceFib +27.2% extensionnot reached34.2028 USD+6.63% from current
- Current32.0773 USD
- SupportFib 23.6% retracementNearesttested 6×31.8934 USD-0.57% from current
- SupportFib 38.2% retracementtested 13×31.2296 USD-2.64% from current
- SupportFib 50% midpointtested 12×30.6932 USD-4.32% from current
- SupportFib 61.8% retracementtested 13×30.1567 USD-5.99% from current
- SupportFib 78.6% retracementtested 12×29.3929 USD-8.37% from current
- SupportFib −27.2% extensionnot reached27.1835 USD-15.26% from current
- SupportFib −61.8% extensionnot reached25.6105 USD-20.16% from current
- SupportFib −100% extensionnot reached23.8739 USD-25.57% from current
How to read this
We take the highest and lowest price of the last 60 bars and cut the gap between them at the classic Fibonacci ratios (23.6%, 38.2%, 50%, 61.8%, 78.6%), plus extensions beyond both ends.
“Tested N×” counts how many of those 60 bars actually traded through the level. A level price has crossed many times is one the market has repeatedly agreed on; a level at 0 is pure geometry the price has never reached.
This is a map of where trading has already happened — not a forecast and not a signal. Price moves through these levels all the time.
Financials
- 52w high
- ¥5,243
- 52w low
- ¥3,660
- 52w change
- 11.45%
- Day high
- ¥5,103
- Day low
- ¥5,002
- P/E (TTM)
- 36.94
- Forward P/E
- 24.94
- PEG
- 26.43
- Price / Book
- 1.57
- Beta (5Y)
- -0.09
- Enterprise value
- 1.41T
- EV / Revenue
- 1.65
- EV / EBITDA
- 14.67
- EPS (TTM)
- ¥136.78
- Forward EPS
- ¥202.57
- Dividend yield
- 3.17%
- Dividend rate
- ¥160
- Payout ratio
- 116.98%
- Revenue (TTM)
- 857.06B
- EBITDA
- 96.13B
- Free cash flow
- -27.57B
- Total cash
- 311.74B
- Total debt
- 271.34B
- Debt / Equity
- 29.08
- Current ratio
- 2.24
- Quick ratio
- 1.44
- Profit margin
- 4.94%
- Gross margin
- 76.70%
- Return on assets
- 2.40%
- Return on equity
- 4.96%
- Shares outstanding
- 282.24M
- Float
- 281.16M
Eisai Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals in Japan. The company operates through pharmaceuticals business and other business segments. It offers Lenvima, a multi-kinase inhibitor which is involved in tumor angiogenesis or tumor malignancy; LEQEMBI, a humanized IgG1 monoclonal antibody against amyloid-beta (Aß) protofibrils; and Dayvigo, a novel small molecule compound. The company also provides prescription drugs; and over-the-counter drugs, as well as focuses on neurology and oncology, and other therapeutic areas. It operates in Europe, the Middle East, Africa, Russia, Oceania, the Americas, China, East Asia, the Global South, and internationally. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
Analyst & Risk
Analysts' consensus via Yahoo Finance — not investment advice.
- Beta (vs S&P 500)
- -0.09
- very stable
- 52-week change
- 11.45%
- Debt / Equity
- 29.08
- very high leverage
- Current ratio
- 2.24
- Quick ratio
- 1.44
- ROE
- 4.96%
- ROA
- 2.40%
- PEG ratio
- 26.43
- EV / Revenue
- 1.65
- EV / EBITDA
- 14.67
- Revenue growth
- 15.60%
- Earnings growth
- 26.00%
- EBITDA
- 96.13B
- Free cash flow
- -27.57B
- Total cash
- 311.74B
- Total debt
- 271.34B
- Insider holdings
- 2.06%
- Institutional
- 57.62%
Related
Other assets in this category.
Learn the terms
Live discussion
Sign in to join the discussion.
- No comments yet. Be the first.